[
  {
    "ts": "2026-02-09T06:15:00+00:00",
    "headline": "Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea",
    "summary": "Allschwil, Switzerland, February 09, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole), by its license partner Pfizer Inc. in the Asia Pacific region and China, exceeded the sales threshold triggering a USD 5 million milestone payment. David Veitch, Basilea’",
    "url": "https://finance.yahoo.com/news/strong-cresemba-isavuconazole-sales-performance-061500767.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "f52292d9-5e40-3db1-82b9-9197fb6612c5",
      "content": {
        "id": "f52292d9-5e40-3db1-82b9-9197fb6612c5",
        "contentType": "STORY",
        "title": "Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea",
        "description": "",
        "summary": "Allschwil, Switzerland, February 09, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole), by its license partner Pfizer Inc. in the Asia Pacific region and China, exceeded the sales threshold triggering a USD 5 million milestone payment. David Veitch, Basilea’",
        "pubDate": "2026-02-09T06:15:00Z",
        "displayTime": "2026-02-09T06:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/ab6630399880cc3ea968f1a9f177a73c",
          "originalWidth": 2843,
          "originalHeight": 970,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xGCvKXGNRUXK1qBvfYMz9w--~B/aD05NzA7dz0yODQzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/ab6630399880cc3ea968f1a9f177a73c.cf.webp",
              "width": 2843,
              "height": 970,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5Qni1lgxkLoNHyUl5nneBA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/ab6630399880cc3ea968f1a9f177a73c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/strong-cresemba-isavuconazole-sales-performance-061500767.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/strong-cresemba-isavuconazole-sales-performance-061500767.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BPMUF"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]